Insurtech
Marrow lands $2M pre-seed to wire AI agents into insurer pricing systems
By Felipe Bernal, . Insurance Wire.
Marrow, a startup that links insurer pricing and underwriting systems to AI agents, has closed a $2 million pre-seed round, Coverager reported. Insurtech Gateway led the raise, with SEED X Liechtenstein, Leo Capital, Portfolio Ventures and angel investors also participating.
What Marrow does
The core problem Marrow is solving is a practical one: AI shopping agents are increasingly being used to help consumers find and buy insurance, but those agents need a structured, compliant way to reach into a carrier's actual pricing and product rules. Marrow sits in between, giving insurers, brokers and managing general agents (MGAs, which are specialist intermediaries that underwrite policies on behalf of carriers) a controlled channel for agent-led sales.
The platform manages which products an agent can access, ensures required disclosures are made, keeps transaction records, and provides compliance monitoring alongside conversion analytics, meaning it tracks how often agent interactions turn into actual sales.
Already in the market
Marrow was co-founded by Tim Graham and Adam Mesout and originated at Founders Factory, a startup studio. The company has been live with Aviva since March, according to Coverager, which gives it at least one named carrier deployment at this early stage.
Why this matters
The funding is small by venture standards, but the problem Marrow is addressing is not. Carriers and MGAs are under real pressure to modernize distribution without losing control of compliance or pricing integrity. AI agents promise faster customer acquisition, but connecting them to legacy underwriting systems without guardrails creates regulatory and operational risk.
Marrow's approach, sitting between the agent and the system rather than replacing either, is one answer to that tension. The compliance monitoring and disclosure controls built into the platform reflect the likelihood that regulators will scrutinize AI-assisted sales closely, particularly around what customers are told before they buy.
The Aviva relationship is the most meaningful signal here. A pre-seed company with a named carrier already in production has cleared a bar that most insurtech startups at this stage have not. Whether Aviva expands that relationship, and whether other carriers follow, will say more about Marrow's prospects than the funding round itself.
For brokers and MGAs evaluating AI distribution tools, the compliance layer is the part worth examining: the question is not whether AI agents can sell insurance, but whether the infrastructure behind them can satisfy regulators and carrier compliance teams at the same time.
Source: https://coverager.com/marrow-raises-2-million/
Insurance Wire provides news and information, not insurance, legal, or financial advice. Consult a qualified professional about your specific needs.